The role of corticotropin-releasing hormone in immune-mediated cutaneous inflammatory disease

Experimental Dermatology

Volumn 15, Issue 3, 2006, Pages 143-153

  O'Kane, Marina ^a,b   Murphy, Evelyn P ^b   Kirby, Brian ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Corticotropin releasing hormone; NURR1; Psoriasis; Stress

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR; NUCLEAR RECEPTOR RELATED FACTOR 1; RETINOIC ACID RECEPTOR; STEROID RECEPTOR; VITAMIN D RECEPTOR;

ACNE; ALOPECIA AREATA; ANGIOGENESIS; CELL ACTIVATION; CELL DIFFERENTIATION; CELL GROWTH; CELL TYPE; DRUG EFFICACY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IN VIVO STUDY; KERATINOCYTE; MAST CELL; MENTAL STRESS; NEUROMODULATION; NONHUMAN; PHYSICAL STRESS; PROTEIN EXPRESSION; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; SEBORRHEA; SKIN INFLAMMATION; SYNOVIUM; UPREGULATION;

ANIMALS; CORTICOTROPIN-RELEASING HORMONE; DERMATITIS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SKIN; STRESS;

EID: 33645951389     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2006.00382.x     Document Type: Review

References (101)

1. Chrousos G P, Gold P W. The concepts of stress system disorders: overview of behavioural and physical homeostasis. JAMA 1992: 267: 1244-1252.
2. Tsigos C, Chrousos G P. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 2002: 53: 865-871.
3. Slominski A, Wortsman J, Luger T et al. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev 2000: 80: 979-1020.
4. Slominski A, Wortsman J, Pisarchik A et al. Cutaneous expression of corticotropin releasing hormone (CRH), urocortin and CRH receptors. FASEB J 2001: 15: 1678-1693.
5. Karalis K P, Sano H, Redwine J et al. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vitro. Science 1991: 254: 421-423.
6. Karalis K P, Kontopoulos E, Muglia L J, Majzoub J A. Corticotropin-releasing hormone deficiency unmasks the proinflammatory effect of epinephrine. Proc Natl Acad Sci USA 1999: 96: 7093-7097.
7. Chrousos G P. The hypothalamic-pituitary-adrenal axis and immune mediated inflammation. N Engl J Med 1995: 332: 1351-1362.
8. Gilbey M P, Spyer K M. Essential organization of the sympathetic nervous system. Baillieres Clin Endocrinol Metab 1993: 7: 259-278.
9. Chrousos G P. Stressors, stress and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. Ann N Y Acad Sci 1998: 851: 311-335.
10. O'Connor T M, O'Halloran D J, Shanahan F. The stress response and the hypothalamic-pituitary-adrenal axis, from molecule to melancholia. QJM 2000: 93: 323-333.
11. Seyle H. A syndrome produced by diverse nocuous agents. Nature 1936: 138: 32.
12. Hench P S, Kendall E C, Slocumb C H, Polley H F. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydro-corticosterone: Compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Mayo Clin Proc 1949: 24: 181-197.
13. Sternberg E M. Neuroendocrine regulation of autoimmunity/inflammatory disease. J Endocrinol 2001: 169: 429-435.
14. Sternberg E M, Hill J M, Chrousos G P et al. Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc Natl Acad Sci USA 1989: 86: 2374-2378.
15. Sternberg E M, Young W S, Bernardini R et al. A central nervous system defect in biosynthesis of corticotropin releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc Natl Acad Sci USA 1989: 86: 4771-4775.
16. Calogero A E, Sternberg E M, Bagdy G et al. Neurotransmitter induced hypothalamic-pituitary-adrenal axis responsiveness is defective in inflammatory disease-susceptible Lewis rats: In vivo and in vitro studies suggesting globally defective hypothalamic secretion of corticotropin releasing hormone. Neuroendocrinology 1992: 55: 600-608.
17. Misiewicz B, Poltorak M, Raybourne R B et al. Intracerebroventricular transplantation of embryonic neuronal tissue from inflammatory resistant into inflammatory susceptible rats suppresses specific components of inflammation. Exp Neurol 1997: 146: 305-314.
18. Fortune D G, Richards D L, Main C J, Griffiths C E M. What patients with psoriasis believe about their condition. J Am Acad Dermatol 1998: 39: 196-201.
19. Fortune D G, Richards H L, Kirby B et al. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol 2003: 139: 752-756.
20. Fortune D G, Richards H L, Kirby B et al. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol 2002: 146: 458 -465.
21. Kirby B, Richards H L, Mason D L et al. Acute stress produces a hypo-cortisolic response in psoriasis patients who are worriers. Br J Dermatol 2002: 147 (Suppl. 62): 31-32.
22. Pisarchik A, Slominski A. Molecular and functional characterisation of novel CRFR1 isoforms from the skin. Eur J Biochem 2004: 271: 2821-2830.
23. Zouboulis C C. The human skin as a hormone target and an endocrine gland. Hormones 2004: 3: 9-26.
24. Wiesner B, Roloff B, Fechner K, Slominski A. Intracellular calcium measurements of single human skin cells after stimulation with corticotropin releasing factor and urocortin using confocal laser scanning microscopy. J Cell Sci 2003: 116: 1261-1268.
25. Fazal N, Slominski A, Choudry M A et al. Effect of CRF and related peptides on calcium signalling in human and rodent melanoma cells. FEBS Lett 1998: 435: 187-190.
26. Seasholtz A F, Valverde R A, Denver R J. Corticotropin-releasing hormone-binding protein: Biochemistry and function from fishes to mammals. J Endocrinol 2002: 175: 89-97.
27. Potter E, Behan D P, Fischer W H et al. Cloning and characterization of the cDNA's for human and rat corticotropin releasing factor binding proteins. Nature 1991: 349: 423-426.
28. Slominski A, Ermak G, Mazurkiewicz J E, Baker J, Wortsman J. Characterization of corticotropin-releasing hormone (CRH) in human skin. J Clin Endocrinol Metab 1998: 83: 1020-1024.
29. Slominski A, Szczesniewski A, Wortsman J. Liquid chromatography-mass spectrometry detection of corticotropin-releasing hormone and proopiomelanocortin-derived peptides in human skin. J Clin Endocrinol Metab 2000: 85: 3582-3588.
30. Slominski A, Roloff B, Curry J, Dahiya M, Szczesniewski A, Wortsman J. The skin produces urocortin. J Clin Endocrinol Metab 2000: 85: 815-823.
31. Pisarchik A, Slominski A. Alternative splicing of CRH-R1 receptors in human and mouse skin: Identification of new variants and their differential expression. FASEB J 2001: 15: 2754-2756.
32. Slominski A, Ermak G, Mihm M. ACTH receptor, CYP11A1, CYP17 and CYP21A2 genes are expressed in skin. J Clin Endocrinol Metab 1996: 81: 2746-2749.
33. Slominski A, Baker J, Ermak G, Chakraborty A P, Awelek J. UVB stimulates production of CRF by human melanocytes. FEBS Lett 1996: 339: 175-176.
34. Slominski A, Zbytek B, Semak I, Sweatman T, Wortsman J. CRH stimulates POMC activity and corticosterone production in dermal fibroblasts. J Neuroimmunol 2005: 162: 97-102.
35. Slominski A, Botchkarev V, Choudhry M et al. Is there a "skin stress system"? Ann N Y Acad Sci 1999: 885: 287-311.
36. Slominski A, Pisarchik A, Tobin J et al. Differential expression of a cutaneous corticitropin-releasing hormone system. Endocrinology 2004: 145: 941-950.
37. Bale T L, Giordano F J, Hickey R P et al. Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularisation. Proc Natl Acad Sci USA 2002: 99: 7734-7739.
38. Chrousos G P, Torpy D J, Gold P W. Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system. Ann Intern Med 1998: 129: 229-240.
39. Crofford L J, Sano H, Karalis K et al. Local secretion of corticotropin-releasing hormone in the joints of Lewis rats with inflammatory arthritis. J Clin Invest 1992: 90: 2555-2564.
40. Merchenthaler I, Hynes M A, Vingh S et al. Immunocytochemical localisation of corticotropin-releasing factor (CRF) in the rat spinal cord. Brian Res 1983: 275: 373-377.
41. Skofitsch G, Zamir N, Helke C et al. Corticotropin releasing factor-like immunoreactivity in sensory ganglia and capsaicin sensitive neurons of the rat central nervous system: Colocalisation with other peptides. Peptides 1985: 6: 307-318.
42. Brouxhon S M, Bellinger D L, Felten D L. Corticotropin-releasing factor (CRF) expression in the immune system following IL-2 administration. Soc Neurosci Abstr 1996: 22: 1353.
43. Martins M, Banks W A, Kastin A J. Transport of CRH from mouse brain directly affects peripheral production of ß-endorphin by the spleen. Am J Physiol 1997: 273: E1083-E1089.
44. Turnbull A V, Vale W, Rivier C. Urocortin, a corticotropin-releasing factor-related mammalian peptide, inhibits edema due to thermal injury in rats. Eur J Pharmacol 1996: 303 (3): 213-216.
45. Correa S G, Riera C M, Spiess J, Bianco I D. Modulation of the inflammatory response by corticotropin releasing factor. Eur J Pharmacol 1997: 319: 85-90.
46. Thomas H A, Ling N, Wei E T. CRF and related peptides as anti-inflammatory agonists. Ann NY Acad Sci 1993: 697: 219-228.
47. Hargreaves K M, Mueller G P, Dubner R, Goldstein D, Dionne R A. Corticotropin-releasing factor (CRF) produces analgesia in humans and rats. Brain Res 1987: 422: 154-157.
48. Torpy D J, Webster E L, Zachman E K et al. Urocortin and inflammation: confounding effects of hypotension on measures of inflammation. Neuroimmunomodulation 1999: 6: 182-186.
49. Wei E T, Gao G C. Corticotropin-releasing factor: An inhibitor of vascular leakage in rat skeletal muscle and brain cortex after injury. Regul Pept 1991: 33: 93-104.
50. Gao G C, Dashwood M R, Wei E T. Corticotropin releasing factor inhibition of substance P induced vascular leakage in rats: Possible sites of action. Peptides 1991: 12: 639-644.
51. Kiang J G, Poree L E, Wei E T. Anti-inflammatory activity of corticotropin releasing factor: II. Mechanisms of action. Proc West Pharmacol Soc 1987: 30: 63-65.
52. Wei E T, Gao G C, Thomas H A. Peripheral anti-inflammatory actions of corticotropin releasing factor. In: Chadwick D J, Marsh J, Ackrill K, eds. Corticotropin-Releasing Hormone. London: John Wiley and Sons, 1993: 258-268.
53. Veraksits A, Bileviciut-Ljungar I, Maaroos J et al. Neuronal mechanisms contribute to corticotropin-releasing factor-induced anti-oedema effect in the rat hind paw. Neuropeptides 2000: 34: 129-134.
54. Dewing S B. Remission of psoriasis associated with cutaneous nerve section. Arch Dermatol 1971: 104: 220-221.
55. Stratigos A J, Katoulis A K, Stavrianeas N G. Spontaneous clearing of psoriasis after stroke. J Am Acad Dermatol 1998: 38: 768-770.
56. Mulherin D, Bresnihan B, FitzGerald O. Digital denervation associated with absence of nail and distal interphalangeal joint involvement in psoriatic arthritis. J Rheumatol 1995: 22: 1211-1212.
57. Kane D, Lockhart J C, Balint P V, Mann C, Ferrell W R, McInnes I B. Protective effect of sensory denervation in inflammatory arthritis (evidence of regulatory neuroimmune pathways in the arthritic joint). Ann Rheum Dis 2005: 64: 325-327.
58. Smith E M, Hughes T K, Cadet P, Stefano G. Corticotropin-releasing factor-induced immunosuppression in human and invertebrate immunocytes. Cell Mol Neurobiol 1992: 12: 473-478.
59. Smith E M, Morrill A C, Meyer W J, Blalock J E. Corticotropin-releasing factor induction of leucocyte-derived immunoreactive ACTH and endorphins. Nature, 1986: 321: 881-882.
60. Jain R, Zwickler D, Hollander C S et al. Corticotropin-releasing factor modulates the immune response to stress in the rat. Endocrinology 1991: 128: 1329-1336.
61. Slominski A, Wortsman J, Linton E, Pisarchik A, Zbytek B. The skin as a model for the immunomodulatory effects of corticotropin-releasing hormone. In: Schaffer M, Stein C, eds. Mind over Matter-regulation of Peripheral Inflammation by the CNS. (Progress in Inflammation Research; M J Parnham, Series editor). Basel: Birkahauser Verlag, 2003: 149-176.
62. Paez Pereda M, Sauer J, Perez Castro C et al. Corticotropin-releasing hormone differentially modulates the interleukin-1 system according to the level of monocyte activation by endotoxin. Endocrinology 1995: 136: 5504-5510.
63. Theorhides T C, Singh L K, Boucher W et al. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 1998: 139: 403 -413.
64. Crompton R, Clifton V L, Bisits A T et al. Corticotropin-releasing hormone causes vasodilation in human skin via mast cell dependent pathways. J Clin Endocrinol Metab 2003: 88: 5427 -5432.
65. Lytinas M, Kempuraj D, Huang M et al. Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists. Int Arch Allergy Immunol 2003: 130: 224-231.
66. Jiang W Y, Chattedee A D, Raychaudhuri S et al. Mast cell density and IL-8 expression in nonlesional and lesional psoriatic skin. Int J Dermatol 2001: 40: 699-703.
67. Naukkarinen A, Harvima I, Paukkonen K et al. Immunohistochemical analysis of sensory nerves and neuropeptides, and their contacts with mast cells in developing and mature psoriatic lesions. Arch Dermatol Res 1993: 285: 341-346.
68. Ackermann L, Harvima I T. Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-alpha and their degranulation is associated with expression of ICAM-1 in the epidermis. Arch Dermatol Res 1998: 290: 353 -359.
69. Jarvikallio A, Harvima I T, Naukkarinen A. Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema. Arch Dermatol Res 2003: 295: 2-7.
70. Huang M, Berry J, Kandere K, Lytinas M, Karalis K, Theoharides T C. Mast cell deficient W/W(v) mice lack stress-induced increase in serum IL-6 levels, as well as in peripheral CRH and vascular permeability, a model of rheumatoid arthritis. Int J Immunopathol Pharmacol 2002: 15: 249-254.
71. Theoharides T C, Spanos C, Pang X et al. Stress-induced intracranial mast cell degranulation: A corticotropin-releasing hormone-mediated effect. Endocrinology 1995: 136: 5745-5750.
72. Kaneko K, Kawana S, Arai K, Shibasaki T. Corticotropin-releasing factor receptor type 1 is involved in the stress-induced exacerbation of chronic contact dermatitis in rats. Exp Dermatol 2003: 12: 47-52.
73. Arbiser J L, Karalis K, Viswanathan A. Corticotropin-releasing hormone stimulates angiogenesis and epithelial tumor growth in the skin. J Invest Dermatol 1999: 113: 838-842.
74. Cao J, Papadopoulou N, Duraisamy K et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 2005: 174: 7665-7675.
75. Kavelaars A, Ballieux R E, Heijnen C J. The role of IL-1 in the corticotropin-releasing factor and arginine- vasopressin-induced secretion of immunoreactive beta-endorphin by human peripheral blood mononuclear cells. J Immunol 1989: 142: 2338-2342.
76. Singh V K, Leu S J. Enhancing effect of corticotropin-releasing neurohormone on the production of interleukin-1 and interleukin-2. Neurosci Lett 1990: 120: 151-154.
77. Angioni S, Petraglia F, Gallinelli A et al. Corticotropin-releasing hormone modulates cytokines release in cultured human peripheral blood mononuclear cells. Life Sci 1993: 53: 1735-1742.
78. Singh V K. Stimulatory effect of corticotropin-releasing neurohormone on human lymphocyte proliferation and interleukin-2 receptor expression. J Neuroimmunol 1989: 23: 257-262.
79. Genedani S, Bernardi M, Baldini M G, Bertolini A. Influence of CRF and alpha-MSH on the migration of human monocytes in vitro. Neuropeptides 1992: 23: 99-102.
80. Anton P M, Gay J, Mykoniatis A et al. Corticotropin-releasing hormone (CRH) requirement in Clostridium difficile toxin A-mediated intestinal inflammation. Proc Natl Acad Sci USA 2004: 101: 8503-8508.
81. Koshida H, Kotake Y. Corticotropin-releasing hormone enhances the superoxide anion production of rabbit peritoneal macrophages stimulated with N-formyl-methionyl-leucyl-phenylalanine. Life Sci 1994: 54: 539-543.
82. Scopa C D, Mastorakos G, Friedman T C et al. Presence of immunoreactive corticotropin releasing hormone in thyroid lesions. Am J Pathol 1994: 145: 1159-1167.
83. Baerwald C G, Panayi G S, Lanchbury J S. Corticotropin releasing hormone promoter region polymorphisms in rheumatoid arthritis. J Rheumatol 1997: 24: 215-216.
84. Fife M, Steer S, Fisher S et al. Association of familial and sporadic rheumatoid arthritis with a single corticotropin-releasing hormone genomic region (8q12.3) haplotype. Arthritis Rheum 2002: 46: 75-82.
85. McEvoy A N, Bresnihan B, Fitzgerald O, Murphy E P. Corticotropin-releasing hormone signalling in synovial tissue vascular endothelium is mediated through the cAMP/CREB pathway. Ann N Y Acad Sci 2002: 966: 119-130.
86. McEvoy A N, Murphy E A, Ponnio T et al. Activation of nuclear orphan receptor NURR1 transcription by NF-kappa B and cyclic adenosine 5′-monophosphate response element-binding protein in rheumatoid arthritis synovial tissue. J Immunol 2002: 168: 2979-2987.
87. McEvoy A N, Bresnihan B, FitzGerald O, Murphy E P. Corticotropin-releasing hormone signalling in synovial tissue from patients with early inflammatory arthritis is mediated by the type 1 alpha corticotropin-releasing hormone receptor. Arthritis Rheum 2001: 44: 1761-1767.
88. McEvoy A N, Bresnihan B, FitzGerald O, Murphy E P. Cyclooxygenase 2-derived prostaglandin E2 production by corticotropin-releasing hormone contributes to the activated cAMP response element binding protein content in rheumatoid arthritis synovial tissue. Arthritis Rheum 2004: 50: 1132-1145.
89. Webster E I Barrientos R M Contoreggi C et al. Cor-ticotropin releasing hormone (CRH) antagonist attenuates adjuvant induced arthritis: Role of CRH in peripheral inflammation. J Rheumatol 2002: 29: 1252-1261.
90. Murphy E P, McEvoy A, Conneely O M et al. Involvement of the nuclear orphan receptor NURR1 in the regulation of corticotropin-releasing hormone expression and actions in human inflammatory arthritis. Arthritis Rheum 2001: 44: 782-793.
91. Kono M, Nagata H, Umemura S et al. In situ expression of corticotropin-releasing hormone (CRH) and proopiomelanocortin (POMC) genes in human skin. FASEB J 2001: 15: 2297-2299.
92. Ralph J A, McEvoy A N, Kane D et al. Modulation of orphan nuclear receptor NURR1 expression by methotrexate in human inflammatory joint disease involves adenosine A2A receptor-mediated responses. J Immunol 2005: 175: 555-565.
93. Zouboulis C C, Eady A, Philpott M et al. What is the pathogenesis of acne? Exp Dermatol 2005: 14: 143-152.
94. Zouboulis C C, Seltmann H, Hiroi N et al. Corticotropin-releasing hormone: An autocrine hormone that promotes lipogenesis in human sebocytes. Proc Natl Acad Sci USA 2002: 99: 7148-7153.
95. Ito N, Ito T, Bettermen A, Paus R. The human hair bulb is a source and target of CRH. J Invest Dermatol 2004: 122: 235-237.
96. Ito N, Ito T, Kromminga A et al. Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal (HPA) axis and synthesize cortisol. FASEB J 2005: 19: 1332-1334.
97. Katsarou-Katsari A, Singh L K, Theoharides T C. Alopecia areata and affected skin CRH receptor upregulation induced by acute emotional stress. Dermatology 2001: 203: 157-161.
98. Quevedo M E, Slominski A, Pinto W, Wei E, Wortsman J. Pleiotropic effects of corticotropin releasing hormone on normal human skin keratinocytes. In Vitro Cell Dev Biol Anim 2001: 37: 50 -54.
99. Zybtek B, Pikula M, Slominski R M et al. Corticotropin-releasing hormone triggers differentiation in HaCaT keratinocytes. Br J Dermatol 2005: 152: 474-480.
100. Slominski A T, Roloff B, Zbytek B et al. Corticotropin-releasing hormone and related peptides can act as bioregulatory factors in human keratinocytes. In Vitro Cell Dev Biol Anim 2000: 36: 211-216.
101. Zbytek B, Slominski A T. Corticotropin-releasing hormone induces keratinocyte differentiation in the adult human epidermis. J Cell Physiol 2005: 203: 118-126.